This is an open-label, intermediate-size patient population expanded access treatmentstudy utilizing 1 dose level of nasal Foralumab (50 µg/dosing day) with the possibilityof increasing to 100 µg/dosing day. The goal of this expanded access clinical trial is toevaluate safety, tolerability, and immune effects of intranasal Foralumab in non-activesecondary progressive multiple sclerosis patients. The primary objective is to treatpatients who have failed current available therapy. Participants will visit the clinicfor testing and follow-up every cycle (3 weeks) while administering the medication athome if able three times weekly.